Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease - A Turkish experience

Akbulut H., Soykan I., Yakaryilmaz F., Icli F., Aksoy F., Haznedaroglu S., ...Daha Fazla

CANCER, cilt.80, sa.1, ss.8-14, 1997 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 80 Sayı: 1
  • Basım Tarihi: 1997
  • Dergi Adı: CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.8-14
  • Anahtar Kelimeler: lymphoma-mucosa-associated lymphoid tissue type, immunoproliferative small intestinal disease, tetracycline, combination chemotherapy, cyclophosphamide, vincristine, procarbazine, prednisolone, ALPHA-CHAIN DISEASE, GASTROINTESTINAL LYMPHOMA, RETROSPECTIVE ANALYSIS, CLINICAL-FEATURES, TURKEY
  • Ankara Üniversitesi Adresli: Evet

Özet

BACKGROUND, Currently, there is no agreement regarding optimal treatment strategies for immunoproliferative small intestinal disease (IPSID). In this article, the authors report the treatment outcomes of a group of 23 Turkish patients with IPSID. METHODS, Between December 1988 and July 1993, 23 consecutive patients with IPSID, including 5 with secretory type, were included in the study. Seven patients with Stage A disease (according to the criteria of Galien et al.) received tetracycline (1 g/day, orally) for a median duration of 7 months (range, 6-11 months) initially, whereas the remaining patients (9 Stage B patients and 7 Stage C patients) received combination chemotherapy (cyclophosphamide, vincristine, procarbazine, and prednisolone [COPP regimen]) followed by tetracycline at a dose of 1 g/day for 6 more months in patients with complete response (CR) after the COPP regimen.